IGF1 and osteosarcoma: Despite the fact that any therapeutic strategy solely targeting the IGF1R is likely insufficient to prevent the activation of downstream signaling pathways in osteosarcoma, this evidence suggests that a genomic-guided approach for the use of anti-IGF agents in patients carrying IGF1R amplification might be considered for future clinical trials.